Agios Pharmaceuticals (NASDAQ:AGIO) stock fell sharply after the company announced it would discontinue development of its sickle cell disease drug, tebapivat, following disappointing Phase 2 trial results. The company will now focus on its other candidate, mitapivat.
Marsh reported a higher second-quarter profit, driven by robust performance in its risk management and consulting divisions as businesses continue to prioritize managing complex threats.
Novo Nordisk has filed a federal lawsuit against rival Eli Lilly, claiming its ads for weight-loss drugs Zepbound and Mounjaro make false and misleading comparisons to Novo's Wegovy and Ozempic. The suit escalates the corporate battle in the lucrative obesity treatment market.
Novartis CEO Vas Narasimhan confirmed he will remain in his role to guide the Swiss drugmaker through a pivotal period, which includes key clinical trial readouts expected in the second half of 2026.
The RTX unit announced a significant reduction in aircraft grounded due to engine maintenance issues, with the problem nearly resolved for Airbus A220 and Embraer E2 models.
British retailer Frasers Group has increased its holding in German fashion house Hugo Boss to 30.28%, a move that legally requires it to make a mandatory takeover offer under German regulations.
An Investing.com analysis identified several U.S. oil and gas companies, including Expand Energy, CNX Resources, and EQT Corp., that exhibit valuation metrics historically favored by Warren Buffett, suggesting potential M&A appeal and significant fair value upside.
A recent technology-led selloff has triggered a broad deterioration in equity positioning, with strategists at Citi noting that the de-risking in U.S. stocks may not have run its course.
The Danish drugmaker has filed a lawsuit in U.S. federal court, claiming rival Eli Lilly's ads for Zepbound and Mounjaro use misleading comparisons to its own Wegovy and Ozempic treatments.
